Vallejo-Vaz, A.J. Bray, S. Villa, G. Brandts, J. Kiru, G. Murphy, J. Banach, M. De Servi, S. Gaita, D. Gouni-Berthold, I. Kees Hovingh, G. Jozwiak, J.J. Jukema, J.W. Gabor Kiss, R. Kownator, S. Iversen, H.K. Maher, V. Masana, L. Parkhomenko, A. Peeters, A. Clifford, P. Raslova, K. Siostrzonek, P. Romeo, S. Tousoulis, D. Vlachopoulos, C. Vrablik, M. Catapano, A.L. Poulter, N.R. Ray, K.K. On behalf of the DA VINCI Study Investigators, Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI, Cardiovascular Drugs and Therapy, 2022, Springer-Verlag, 0920-3206, 1573-7241